with dual 503A/503B licensing and massive GLP-1 production capacity Key Strengths: Dual 503A and 503B registered facility enabling both patient-specific and bulk compounding at scale One of the first pharmacies to offer compounded semaglutide with full potency verification and published COAs State-of-the-art 140,000 sq ft FDA-registered facility in Houston with dedicated cleanroom suites Extensive tirzepatide and semaglutide formulations including sublingual and injectable options Notable: Empower processes over 100,000 semaglutide prescriptions monthly, making them the single largest volume compounder of GLP-1 therapies in the nation
Furthermore, BPC-157 exhibits anti-inflammatory properties through inhibition of pro-inflammatory cytokine production and modulation of nuclear factor-kappa B signaling pathways
10.1016/j.redox.2020.101702 [DOI] [PMC free article] [PubMed] [Google Scholar] Liu S, Liu J, Wang Y, Deng F, Deng Z (2025) Oxidative stress: signaling pathways, biological functions, and disease
Distribution and binding Once absorbed, tirzepatide binds extensively to plasma albumin, with approximately 99 percent protein binding
.webp)
